Trial Profile
Switching From Atripla to Stribild Leads to Improvements in Central Nervous System Side Effects and Sleep Disturbances
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Oct 2016 Results presented at the IDWeek 2016
- 21 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 25 Jun 2015 New trial record